Key Points
- Tempus AI director David Epstein sold 370 shares for $27,487.30, reducing his stake by 1.2% to 30,474 shares. The sale was made under a pre-arranged Rule 10b5-1 plan.
- The company reported quarterly revenue of $411.5 million, up 23.1% year over year, and EPS of $0.07, beating analyst expectations for a loss of $0.09.
- Analysts raised price targets after the results, though views remain mixed: the article cites a consensus “Hold” rating and notes concerns about valuation and acquisition integration risks.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David Epstein sold 370 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $74.29, for a total value of $27,487.30. Following the sale, the director directly owned 30,474 shares of the company's stock, valued at $2,263,913.46. This represents a 1.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Trading Down 2.8%
Shares of TEM stock opened at $75.61 on Thursday. The company has a market cap of $13.64 billion, a P/E ratio of -71.33 and a beta of 3.61. The stock has a 50 day simple moving average of $71.17 and a two-hundred day simple moving average of $57.20. The company has a debt-to-equity ratio of 2.70, a quick ratio of 3.16 and a current ratio of 2.61. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $89.09.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. The firm had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The company's revenue was up 23.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.46) earnings per share. Research analysts forecast that Tempus AI, Inc. will post -1.45 earnings per share for the current year.
Key Stories Impacting Tempus AI
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Tempus reported third-quarter revenue of $411.5 million, up 23.1% year over year, and earnings of $0.07 per share—above expectations for a loss. The company also raised its 2026 revenue outlook to about $1.6 billion, citing oncology demand, data partnerships and potential reimbursement-driven pricing gains. Tempus Reports Third Quarter 2026 Results Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
- Positive Sentiment: Several analysts raised their price targets after the results: HC Wainwright to $85, and Baird and Cantor Fitzgerald to $92, with buy/outperform/overweight ratings. Analysts Boost Their Forecasts Following Strong Q3 Results
- Neutral Sentiment: The stock had climbed sharply following earnings, but one report argued it looked fully valued after its recent run. UBS maintained a Hold rating, citing solid oncology execution offset by weaker hereditary testing. Tempus AI Stock Looks Fully Priced Following Its Run UBS Hold Rating
- Negative Sentiment: The CEO and a director disclosed small stock sales, both conducted under pre-arranged Rule 10b5-1 plans. The limited size and planned nature make these sales a relatively weak signal, but they may add to near-term caution. SEC filing
- Negative Sentiment: Investors also face potential integration risks tied to Tempus AI’s proposed Personalis acquisition, which could add execution uncertainty. Personalis Acquisition Integration Risks
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. TD Cowen reissued a "buy" rating on shares of Tempus AI in a research note on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price target on shares of Tempus AI from $45.00 to $70.00 and gave the company a "neutral" rating in a research note on Wednesday, October 14th. Raymond James Financial set a $80.00 price target on shares of Tempus AI in a research note on Wednesday, September 2nd. Stifel Nicolaus dropped their price objective on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a report on Monday, August 3rd. Finally, Piper Sandler raised shares of Tempus AI from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Eleven investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Tempus AI currently has a consensus rating of "Hold" and an average price target of $79.37.
Get Our Latest Stock Analysis on TEM
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Fulcrum Asset Management LLP purchased a new stake in Tempus AI in the 3rd quarter valued at $420,000. Pictet Asset Management Holding SA lifted its stake in Tempus AI by 2,965.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company's stock valued at $41,233,000 after acquiring an additional 486,493 shares in the last quarter. Heritage Family Offices LLP bought a new position in Tempus AI during the 3rd quarter valued at $45,000. QTR Family Wealth LLC bought a new position in Tempus AI during the 3rd quarter valued at $260,000. Finally, Commonwealth Equity Services LLC boosted its holdings in Tempus AI by 5.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 26,726 shares of the company's stock worth $2,189,000 after acquiring an additional 1,455 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.
Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
